Polymer nanoparticles containing azabodipy for in vitro multitherapy

In this thesis, a chemiluminescent multitherapy agent was designed. This innovative design aims to develop a novel compound (1) that combines a chemiluminescent unit sensitive to reactive oxygen species (ROS) with the AzaBODIPY scaffold, which possesses therapeutic properties and potential for photodynamic therapy, photothermal therapy, and sonodynamic therapy. The AzaBODIPY scaffold is central to this platform, enhancing therapeutic efficacy and demonstrating high performance in treatment processes. The triple therapy approach aims to provide a higher therapeutic effect on cancer cells, with the expectation of increased efficacy and significant inhibition of targeted cells during treatment The target compound, AzaBODIPY 1, was obtained through a series of synthesis steps, and its photophysical properties were determined. The chemiluminogenic, photodynamic, photothermal, and sonodynamic activities of the target compound were assessed through subsequent chemical tests. It was found that the photophysical properties were pH-dependent. Additionally, it was determined that the target AzaBODIPY 1 exhibits chemiluminescence in the presence of 1O2 and CIO- and function as a chemiluminogenic sensor. In the final stage, nanoformulation of AzaBODIPY 1 was investigated for in vitro tests. In vitro studies demonstrated that the nanomaterial is highly effective in sonodynamic, photodynamic and photothermal therapies, as well as in dual and/or triple combinations of these therapies on cancer cells. Consequently, nanomaterials, which hold great promise for sonodynamic, photodynamic and photothermal therapy have been obtained for the treatment of cancer.